Chatterjee Kshitij, Wu Chao-Ping, Bhardwaj Abhishek, Siuba Matthew
Fellow, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic
Fellow, Department of Pulmonary Medicine, Respiratory Institute, Cleveland Clinic.
Cleve Clin J Med. 2020 Aug 20. doi: 10.3949/ccjm.87a.ccc059.
Most antiviral or immunomodulatory therapies investigated for use in patients with COVID-19 have failed to show any mortality benefit. Similar to the previous pandemics caused by respiratory viruses, the role and benefit of corticosteroids has been under debate in COVID-19-related pulmonary disease. In this consult, we discuss the evidence regarding the efficacy of corticosteroid use in hospitalized patients with COVID-19, including data from the first randomized controlled trial on this subject.
大多数针对COVID-19患者研究的抗病毒或免疫调节疗法均未显示出任何降低死亡率的益处。与之前由呼吸道病毒引起的大流行类似，皮质类固醇在COVID-19相关肺部疾病中的作用和益处一直存在争议。在本会诊中，我们讨论了关于皮质类固醇用于COVID-19住院患者疗效的证据，包括来自该主题的第一项随机对照试验的数据。
